Pay in 4 interest-free payments of $6.09 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
The Company is developing nimacimab as a potential orthogonal add-on therapy for patients with obesity who are experienced on or have plateaued with GLP-1-based treatment, targeting clinically meaningful incremental weight loss, improved body composition, and reduced weight regain without added gastrointestinal or neuropsychiatric burden
It has an elimination half-life of around 5 days, allowing for once-weekly dosing
Maybe theyre battling depression and obesity, and traditional psychiatry isnt addressing the metabolic piece
I have had the third shot of the initial dosage
US$ 21.09
US$ 26.90
US$ 29.09
US$ 24.39
US$ 20.70
US$ 20.10
US$ 21.12
US$ 28.46
